Tricog, a leading AI firm specializing in heart health, has raised $8.5 million in a Series B2 funding round led by OMRON HEALTHCARE and Sony Innovation Fund, both based in Japan. Existing investors UTEC – The University of Tokyo Edge Capital, Inventus Partners LLP, and SG Innovate also participated in the funding round. This brings the total raised by Tricog to $30 million.
Tricog’s AI platform, developed in collaboration with medical experts, has touched the lives of more than 12 million patients worldwide, with half a million patients added to the care pathway for critical diseases. Tricog aims to make cardiac diagnosis and management more accessible and affordable by strengthening partnerships with government and large private healthcare networks and developing state-of-the-art technology for next-generation products, enabling wider reach in patient populations and disease conditions.
In addition to its heart health AI platform, Tricog has recently developed the TriCare platform, an integrated solution for chronic disease management that addresses the global healthcare challenge of heart failure within the US healthcare system and Asia. The TriCare platform enables remote management of heart disease using medical data from connected devices at home and wearable devices such as the Apple Watch. The TriCare platform addresses a growing $110 billion market segment opportunity.
Tricog was founded in 2015 by Dr. Charit Bhograj, Dr. Zainul Charbiwala, and Dr. Udayan Dasgupta. Its platform has been deployed in over 5,000 cath labs, hospitals, clinics, and diagnostic centers to help diagnose and manage patients with critical cardiac diseases, including heart attacks. The platform is currently deployed across five state governments and numerous private healthcare networks, significantly reducing mortality and morbidity.
Commenting on the funding Dr. Charit Bhograj, Founder & CEO, Tricog Health said, “The last five years have witnessed tremendous advancements in our AI and technology platform that have allowed us to serve millions of patients across multiple continents. With this round, we are committed to expanding our reach to Asia and Africa and our footprint in the US healthcare market. In addition, our strategic partnerships will allow us, for the first time, to address the needs of heart patients at home, the direction where healthcare will be.”